person · Reporting owner
Henderson Mary Elizabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | SVP, Technical Operations | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 23,815 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Tax withholding · Disposed 1,412 · Balance 23,830 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-09-08 · Tax withholding · Disposed 15 · Balance 23,815 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 20:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 15 | $241.20 | $3,618.00 |
DisclosureSEC source: 0001989533-26-000019 · edgardoc.xml · nonDerivative · entry 2 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,815 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,412 | $243.03 | $343,158.22 |
DisclosureSEC source: 0001989533-26-000019 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 16 | $244.64 | $3,914.31 |
DisclosureSEC source: 0001989533-26-000015 · edgardoc.xml · nonDerivative · entry 2 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,242 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,076 | $241.39 | $501,125.64 |
DisclosureSEC source: 0001989533-26-000015 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,258 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,394 | $186.75 | $260,325.32 |
DisclosureSEC source: 0001989533-26-000011 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,334 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.1633 to $186.7558. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:04 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,343 | $194.49 | $1,039,134.42 |
DisclosureSEC source: 0001989533-26-000006 · edgardoc.xml · nonDerivative · entry 2 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,728 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $194.1900 to $194.5000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:04 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 4,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001989533-26-000006 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,071 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001989533-26-000002 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,624 F1 · kind: Represents ordinary shares of the Issuer that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,238 | $169.51 | $379,365.62 |
DisclosureSEC source: 0001989533-25-000008 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,508 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $169.00 to $169.82. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,331 | $180.40 | $240,112.40 |
DisclosureSEC source: 0001989533-25-000005 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,746 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 698 | $138.23 | $96,484.54 |
DisclosureSEC source: 0001765581-25-000033 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,077 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000018 · edgardoc.xml · nonDerivative · entry 2 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,775 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000018 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,923 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| September 06, 2024 Filed Sep 11, 2024 15:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,410 | $108.30 | $152,703.00 |
DisclosureSEC source: 0001765581-24-000084 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,531 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000026 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,941 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000082 · edgardoc.xml · nonDerivative · entry 1 Henderson Mary Elizabeth · CIK 0001989533 · SVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,763 F1 · kind: These restricted stock units are granted pursuant to the Issuer's GW Pharmaceuticals Long Term Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of September 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.